Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
نویسندگان
چکیده
Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. The incidence of hepatocellular carcinoma is increasing in the United States and worldwide. Orthotopic liver transplantation (OLT) is a viable and potentially curative option for selected patients with HCC. Locoregional therapy has been used to control HCC before transplantation because of the limited number of donor organs, to prevent tumor progression, and to decrease the incidence of dropouts from the transplant waiting list. Traditionally, multiple investigational locoregional modalities such as tumor resection, radiofrequency ablation, transarterial chemoembolization, and systemic chemotherapy have been used as "bridging" therapies. While the investigation of novel neoadjuvant treatments is justified in an effort to prevent tumor progression, the absence of randomized controlled trials leaves uncertainty about the utility of these maneuvers in improving outcome. This review summarizes the current data on the different modalities used worldwide in the neoadjuvant treatment of hepatocellular carcinoma, the rationale for these approaches, efficacy, potential complications, and future prospects.
منابع مشابه
Evaluation of Silibinin effects on the Viability of HepG2 (Human hepatocellular liver carcinoma) and HUVEC (Human Umbilical Vein Endothelial) cell lines
Human hepatocellular carcinoma is one of the most common recurrent malignancies, for as much as, there is no effective therapy. Silibinin, a widely used drug and supplement for various liver disorders, demonstrated anticancer effects against human hepatocellular carcinoma, human prostate adenocarcinoma cells, human breast carcinoma cells, human ectocervical carcinoma cells, and human colon canc...
متن کاملEvaluation of Silibinin effects on the Viability of HepG2 (Human hepatocellular liver carcinoma) and HUVEC (Human Umbilical Vein Endothelial) cell lines
Human hepatocellular carcinoma is one of the most common recurrent malignancies, for as much as, there is no effective therapy. Silibinin, a widely used drug and supplement for various liver disorders, demonstrated anticancer effects against human hepatocellular carcinoma, human prostate adenocarcinoma cells, human breast carcinoma cells, human ectocervical carcinoma cells, and human colon canc...
متن کاملDoes neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
PURPOSE We aimed to compare the overall (OS) and disease-free survival (DFS) of patients undergoing orthotopic liver transplant (OLT) for hepatocellular carcinoma who did and did not have neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS This is a retrospective study of 94 patients with HCC transplanted between 2000 and 2014 in a single tertiary cen...
متن کاملA Review on the Efficacy of Chemotherapy in Locally Advanced Head and Neck Cancers
Background and Aims: Chemotherapy is utilized as a part of combined-modality programs to achieve organ preservation and improve survival in patients with locally advanced head and neck cancer. Combinedmodality protocols can be used in three forms: a) neoadjuvant induction chemotherapy before definitive surgery or radiotherapy; b) concomitant chemoradiotherapy; and c) sequential therapy consisti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Oncology
دوره 21 9 شماره
صفحات -
تاریخ انتشار 2007